Facial Injectable Market Size, Share & Industry Trends Analysis Report By End-use (MedSpa, Dermatology Clinics and Hospitals), By Product, By Application, By Regional Outlook and Forecast, 2023

The Global Facial Injectable Market size is expected to reach $22.5 billion by 2029, rising at a market growth of 10.1% CAGR during the forecast period.

Facial Line Correction constitutes the largest part of the market as the ageing population continues to increase, and as a result, there is a huge demand for surgeries and treatments that can make people look younger. Hence, generated $3,998 million revenue in 2022. Around 727 million individuals are 65 years of age or older, globally, according to the United Nations Department of Economic and Social Affairs. Additionally, there are increasingly more people in their 50s and older. Some of the factors impacting the market are growing popularity of facial injectables among men, growing demand for aesthetic procedures, and possible side effects of facial injectables.

The fact that more men are anticipated to use facial-type injectables in the next years is one of the most distinctive and pervasive trends currently seen in the market. During the forecast period, it is anticipated that this specific trend will favorably impact market expansion. During the forecast period, the male population is anticipated to embrace a variety of fillers, including dermal fillers and botulinum toxin. Aesthetic procedures are in greater demand nowadays due to several elements that have been developed, as well as increased awareness. Furthermore, there has been a significant rise in disposable income as economic progress occurs worldwide in developing nations. As a result, an increasing number of people are using various filler injections to enhance their aesthetic appearance.

However, Despite a significant and ongoing rise in demand for aesthetic operations like fillers and botulinum toxin, several obstacles limit market expansion. For instance, these procedures can have unpleasant side effects like pain, bruising, bumps, lumps, swelling at the injection site, infection, and redness. Additionally, if the facial injectable is injected into a blood vessel, it has occasionally resulted in rare but severe side effects, including eyesight loss, blurred vision, scarring, and blindness.

Cosmetic surgery offices and dermatology practices noticed a considerable rise in virtual consultations during the lockdown. As more regions abolish COVID-19 restrictions, this unmet demand is predicted to manifest in large numbers. In light of this, it can be stated that COVID-19 had a negative impact on the market initially but has been witnessing speedy recovery and significant growth since 2021.

Product Outlook

Based on product, the market is segmented into collagen & PMMA microspheres, hyaluronic acid (HA), botulinum toxin type A, calcium hydroxylapatite (CaHA), poly-L-lactic acid (PLLA), and others. The hyaluronic acid (HA) segment garnered a significant revenue share in the market in 2022. The ability of hyaluronic acid (HA) to keep moisture in the skin and give it a healthier appearance is widely established. Hyaluronic acid's moisture-binding ability helps increase and maintain the essential moisture that keeps the skin plump. Glycosaminoglycans such as hyaluronic acid (HA) support the maintenance of stable, protected, and continuously renewing skin. In the fluid around joints and the eyes, HA is more concentrated.

Application Outlook

On the basis of application, the market is fragmented into facial line correction, lip augmentation, face lift, acne scar treatment, lipoatrophy treatment and others. In 2022, the facial line segment witnessed the largest revenue share in the market. This development is attributable to the rising popularity of facial injectables for cosmetic operations, including treating facial wrinkles, lip lines, and facial lines, to mention a few. The market is anticipated to rise due to rising disposable income and increased awareness of cosmetic procedures.

End-use Outlook

By end-use, the market is bifurcated into medSpa, dermatology clinics, and hospitals. In 2022, the medSpa segment held the highest revenue share in the market. A medspa is a place where cosmetic procedures are carried out under the guidance of a qualified doctor. These facilities offer non-invasive procedures like face injections, skin rejuvenation, non-invasive body contouring, and laser treatments, all carried out by qualified specialists. These establishments must adhere to all governmental regulations and requirements and must be owned by physicians.

Regional Outlook

Region wise, the market is analysed across North America, Europe, Asia Pacific and LAMEA. In 2022, the North America region led the market with the maximum revenue share. Over the projected period, the huge elderly populations in the U.S. and Canada are anticipated to fuel demand for facial injectables. The market's expansion is also fueled by the introduction of new products by major market players in North America. The population between the ages of 25 and 65 has grown, and this age group is more prone to skin disorders such as skin wrinkling.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Suneva Medical, Inc., Medytox Inc., Sinclair Pharma Ltd., Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group), Anika Therapeutics, Inc., Prollenium Medical Technologies Inc., Galderma S.A., and Allergan PLC (AbbVie, Inc.).

Strategies Deployed in the Market

Oct-2022: Prollenium Medical Technologies Inc. took over SoftFil, a French brand specializing in aesthetic medicine. By developing creative synergies between SoftFil and Prollenium's brand Revanesse, the acquisition aimed to keep the brand's identity and independence, while strengthening its international presence.
Feb-2022: Merz Aesthetics launched Radiesse Lidocaine injectable implant for deep injection for soft tissue augmentation. With this product launch, the company aimed to mark the first and only calcium hydroxylapatite offerings across the United States. Moreover, Radiesse Lidocaine is also the only injectable treatment approved by the FDA for the improvement of jawline contour.
Jan-2022: Galderma took over ALASTIN Skincare, a specialty aesthetics company. This acquisition aimed to improve the integrated dermatology platform of Galderma with the addition of a comprehensive range of scientifically proven solutions for daily skincare regimens.
Sep-2021: Galderma teamed up with Sofregen Medical, a medical device company pioneering the use of silk protein for tissue building and regeneration. The collaboration aimed to expand the company's capabilities built on decades of science-based esthetics innovation and an innovative heritage in bio stimulator & hyaluronic acid (HA) fillers. In addition, this would allow immediate volume restoration and provide a structure that facilitates new tissue generation.
Apr-2021: Sinclair Pharma Ltd. revealed new Hyaluronic Acid (HA) filler MaiLi. The new HA filler provides supple volume, projection power, and elasticity while allowing for natural movement. In addition, MaiLi Extreme uses 24% less gel than the market leader's product to achieve the same volumizing effect.
Jan-2021: Merz Aesthetics teamed up with Candela Medical, an American laser company. Following this collaboration, the companies would work on expanding their product offerings along with complying with the demands of patients for full-spectrum aesthetic care.
Apr-2020: Sinclair Pharma Limited received approval from Health Canada for the InstaLift, a non-surgical procedure that elevates and repositions facial tissue. With this approval, the brand enters the Canadian market for the first time, further demonstrating its dominance within the aesthetics industry.
Apr-2019: Merz introduced Belotero Revive, a dermal filler product containing a unique combination of hyaluronic acid (HA) and glycerol. The new product is developed to enhance hydration, elasticity, and firmness of the skin and to eliminate the appearance of fine lines. Through this product launch, the company would offer physicians a new dermal injectable that can be utilized for early intervention as well as beautification; to assist fulfills the unique needs of individual patients.

Scope of the Study

Market Segments Covered in the Report:

By End-use

MedSpa
Dermatology Clinics
Hospitals

By Product

Botulinum Toxin Type A
Calcium Hydroxylapatite (CaHA)
Poly-L-Lactic Acid (PLLA)
Collagen & PMMA Microspheres
Hyaluronic Acid (HA)
Others

By Application

Facial Line Correction
Face Lift
Lip Augmentation
Acne Scar Treatment
Lipoatrophy Treatment
Others

By Geography

North America
US
Canada
Mexico
Rest of North America

Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Asia Pacific
China
Japan
India
South Korea
Singapore
Taiwan
Rest of Asia Pacific

LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

Ipsen Pharma Biotech SAS
Merz Pharma GmbH & Co. KGaA
Suneva Medical, Inc.
Medytox Inc.
Sinclair Pharma Ltd.
Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group)
Anika Therapeutics, Inc.
Prollenium Medical Technologies Inc.
Galderma S.A.
Allergan PLC (AbbVie, Inc.)

Unique Offerings

Exhaustive coverage
The highest number of Market tables and figures
Subscription-based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Facial Injectable Market, by End-use
1.4.2 Global Facial Injectable Market, by Product
1.4.3 Global Facial Injectable Market, by Application
1.4.4 Global Facial Injectable Market, by Geography
1.5 Research Methodology

Chapter 2. Market Overview

2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Facial Injectable Market by End-use

3.1 Global MedSpa Market by Region
3.2 Global Dermatology Clinics Market by Region
3.3 Global Hospitals Market by Region

Chapter 4. Global Facial Injectable Market by Product

4.1 Global Botulinum Toxin Type A Market by Region
4.2 Global Calcium Hydroxylapatite (CaHA) Market by Region
4.3 Global Poly-L-Lactic Acid (PLLA) Market by Region
4.4 Global Collagen & PMMA Microspheres Market by Region
4.5 Global Hyaluronic Acid (HA) Market by Region
4.6 Global Others Market by Region

Chapter 5. Global Facial Injectable Market by Application

5.1 Global Facial Line Correction Market by Region
5.2 Global Face Lift Market by Region
5.3 Global Lip Augmentation Market by Region
5.4 Global Acne Scar Treatment Market by Region
5.5 Global Lipoatrophy Treatment Market by Region
5.6 Global Others Market by Region

Chapter 6. Global Facial Injectable Market by Region

6.1 North America Facial Injectable Market
6.1.1 North America Facial Injectable Market by End-use
6.1.1.1 North America MedSpa Market by Country
6.1.1.2 North America Dermatology Clinics Market by Country
6.1.1.3 North America Hospitals Market by Country
6.1.2 North America Facial Injectable Market by Product
6.1.2.1 North America Botulinum Toxin Type A Market by Country
6.1.2.2 North America Calcium Hydroxylapatite (CaHA) Market by Country
6.1.2.3 North America Poly-L-Lactic Acid (PLLA) Market by Country
6.1.2.4 North America Collagen & PMMA Microspheres Market by Country
6.1.2.5 North America Hyaluronic Acid (HA) Market by Country
6.1.2.6 North America Others Market by Country
6.1.3 North America Facial Injectable Market by Application
6.1.3.1 North America Facial Line Correction Market by Country
6.1.3.2 North America Face Lift Market by Country
6.1.3.3 North America Lip Augmentation Market by Country
6.1.3.4 North America Acne Scar Treatment Market by Country
6.1.3.5 North America Lipoatrophy Treatment Market by Country
6.1.3.6 North America Others Market by Country
6.1.4 North America Facial Injectable Market by Country
6.1.4.1 US Facial Injectable Market
6.1.4.1.1 US Facial Injectable Market by End-use
6.1.4.1.2 US Facial Injectable Market by Product
6.1.4.1.3 US Facial Injectable Market by Application
6.1.4.2 Canada Facial Injectable Market
6.1.4.2.1 Canada Facial Injectable Market by End-use
6.1.4.2.2 Canada Facial Injectable Market by Product
6.1.4.2.3 Canada Facial Injectable Market by Application
6.1.4.3 Mexico Facial Injectable Market
6.1.4.3.1 Mexico Facial Injectable Market by End-use
6.1.4.3.2 Mexico Facial Injectable Market by Product
6.1.4.3.3 Mexico Facial Injectable Market by Application
6.1.4.4 Rest of North America Facial Injectable Market
6.1.4.4.1 Rest of North America Facial Injectable Market by End-use
6.1.4.4.2 Rest of North America Facial Injectable Market by Product
6.1.4.4.3 Rest of North America Facial Injectable Market by Application
6.2 Europe Facial Injectable Market
6.2.1 Europe Facial Injectable Market by End-use
6.2.1.1 Europe MedSpa Market by Country
6.2.1.2 Europe Dermatology Clinics Market by Country
6.2.1.3 Europe Hospitals Market by Country
6.2.2 Europe Facial Injectable Market by Product
6.2.2.1 Europe Botulinum Toxin Type A Market by Country
6.2.2.2 Europe Calcium Hydroxylapatite (CaHA) Market by Country
6.2.2.3 Europe Poly-L-Lactic Acid (PLLA) Market by Country
6.2.2.4 Europe Collagen & PMMA Microspheres Market by Country
6.2.2.5 Europe Hyaluronic Acid (HA) Market by Country
6.2.2.6 Europe Others Market by Country
6.2.3 Europe Facial Injectable Market by Application
6.2.3.1 Europe Facial Line Correction Market by Country
6.2.3.2 Europe Face Lift Market by Country
6.2.3.3 Europe Lip Augmentation Market by Country
6.2.3.4 Europe Acne Scar Treatment Market by Country
6.2.3.5 Europe Lipoatrophy Treatment Market by Country
6.2.3.6 Europe Others Market by Country
6.2.4 Europe Facial Injectable Market by Country
6.2.4.1 Germany Facial Injectable Market
6.2.4.1.1 Germany Facial Injectable Market by End-use
6.2.4.1.2 Germany Facial Injectable Market by Product
6.2.4.1.3 Germany Facial Injectable Market by Application
6.2.4.2 UK Facial Injectable Market
6.2.4.2.1 UK Facial Injectable Market by End-use
6.2.4.2.2 UK Facial Injectable Market by Product
6.2.4.2.3 UK Facial Injectable Market by Application
6.2.4.3 France Facial Injectable Market
6.2.4.3.1 France Facial Injectable Market by End-use
6.2.4.3.2 France Facial Injectable Market by Product
6.2.4.3.3 France Facial Injectable Market by Application
6.2.4.4 Russia Facial Injectable Market
6.2.4.4.1 Russia Facial Injectable Market by End-use
6.2.4.4.2 Russia Facial Injectable Market by Product
6.2.4.4.3 Russia Facial Injectable Market by Application
6.2.4.5 Spain Facial Injectable Market
6.2.4.5.1 Spain Facial Injectable Market by End-use
6.2.4.5.2 Spain Facial Injectable Market by Product
6.2.4.5.3 Spain Facial Injectable Market by Application
6.2.4.6 Italy Facial Injectable Market
6.2.4.6.1 Italy Facial Injectable Market by End-use
6.2.4.6.2 Italy Facial Injectable Market by Product
6.2.4.6.3 Italy Facial Injectable Market by Application
6.2.4.7 Rest of Europe Facial Injectable Market
6.2.4.7.1 Rest of Europe Facial Injectable Market by End-use
6.2.4.7.2 Rest of Europe Facial Injectable Market by Product
6.2.4.7.3 Rest of Europe Facial Injectable Market by Application
6.3 Asia Pacific Facial Injectable Market
6.3.1 Asia Pacific Facial Injectable Market by End-use
6.3.1.1 Asia Pacific MedSpa Market by Country
6.3.1.2 Asia Pacific Dermatology Clinics Market by Country
6.3.1.3 Asia Pacific Hospitals Market by Country
6.3.2 Asia Pacific Facial Injectable Market by Product
6.3.2.1 Asia Pacific Botulinum Toxin Type A Market by Country
6.3.2.2 Asia Pacific Calcium Hydroxylapatite (CaHA) Market by Country
6.3.2.3 Asia Pacific Poly-L-Lactic Acid (PLLA) Market by Country
6.3.2.4 Asia Pacific Collagen & PMMA Microspheres Market by Country
6.3.2.5 Asia Pacific Hyaluronic Acid (HA) Market by Country
6.3.2.6 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Facial Injectable Market by Application
6.3.3.1 Asia Pacific Facial Line Correction Market by Country
6.3.3.2 Asia Pacific Face Lift Market by Country
6.3.3.3 Asia Pacific Lip Augmentation Market by Country
6.3.3.4 Asia Pacific Acne Scar Treatment Market by Country
6.3.3.5 Asia Pacific Lipoatrophy Treatment Market by Country
6.3.3.6 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Facial Injectable Market by Country
6.3.4.1 China Facial Injectable Market
6.3.4.1.1 China Facial Injectable Market by End-use
6.3.4.1.2 China Facial Injectable Market by Product
6.3.4.1.3 China Facial Injectable Market by Application
6.3.4.2 Japan Facial Injectable Market
6.3.4.2.1 Japan Facial Injectable Market by End-use
6.3.4.2.2 Japan Facial Injectable Market by Product
6.3.4.2.3 Japan Facial Injectable Market by Application
6.3.4.3 Taiwan Facial Injectable Market
6.3.4.3.1 Taiwan Facial Injectable Market by End-use
6.3.4.3.2 Taiwan Facial Injectable Market by Product
6.3.4.3.3 Taiwan Facial Injectable Market by Application
6.3.4.4 India Facial Injectable Market
6.3.4.4.1 India Facial Injectable Market by End-use
6.3.4.4.2 India Facial Injectable Market by Product
6.3.4.4.3 India Facial Injectable Market by Application
6.3.4.5 South Korea Facial Injectable Market
6.3.4.5.1 South Korea Facial Injectable Market by End-use
6.3.4.5.2 South Korea Facial Injectable Market by Product
6.3.4.5.3 South Korea Facial Injectable Market by Application
6.3.4.6 Singapore Facial Injectable Market
6.3.4.6.1 Singapore Facial Injectable Market by End-use
6.3.4.6.2 Singapore Facial Injectable Market by Product
6.3.4.6.3 Singapore Facial Injectable Market by Application
6.3.4.7 Rest of Asia Pacific Facial Injectable Market
6.3.4.7.1 Rest of Asia Pacific Facial Injectable Market by End-use
6.3.4.7.2 Rest of Asia Pacific Facial Injectable Market by Product
6.3.4.7.3 Rest of Asia Pacific Facial Injectable Market by Application
6.4 LAMEA Facial Injectable Market
6.4.1 LAMEA Facial Injectable Market by End-use
6.4.1.1 LAMEA MedSpa Market by Country
6.4.1.2 LAMEA Dermatology Clinics Market by Country
6.4.1.3 LAMEA Hospitals Market by Country
6.4.2 LAMEA Facial Injectable Market by Product
6.4.2.1 LAMEA Botulinum Toxin Type A Market by Country
6.4.2.2 LAMEA Calcium Hydroxylapatite (CaHA) Market by Country
6.4.2.3 LAMEA Poly-L-Lactic Acid (PLLA) Market by Country
6.4.2.4 LAMEA Collagen & PMMA Microspheres Market by Country
6.4.2.5 LAMEA Hyaluronic Acid (HA) Market by Country
6.4.2.6 LAMEA Others Market by Country
6.4.3 LAMEA Facial Injectable Market by Application
6.4.3.1 LAMEA Facial Line Correction Market by Country
6.4.3.2 LAMEA Face Lift Market by Country
6.4.3.3 LAMEA Lip Augmentation Market by Country
6.4.3.4 LAMEA Acne Scar Treatment Market by Country
6.4.3.5 LAMEA Lipoatrophy Treatment Market by Country
6.4.3.6 LAMEA Others Market by Country
6.4.4 LAMEA Facial Injectable Market by Country
6.4.4.1 Brazil Facial Injectable Market
6.4.4.1.1 Brazil Facial Injectable Market by End-use
6.4.4.1.2 Brazil Facial Injectable Market by Product
6.4.4.1.3 Brazil Facial Injectable Market by Application
6.4.4.2 Argentina Facial Injectable Market
6.4.4.2.1 Argentina Facial Injectable Market by End-use
6.4.4.2.2 Argentina Facial Injectable Market by Product
6.4.4.2.3 Argentina Facial Injectable Market by Application
6.4.4.3 UAE Facial Injectable Market
6.4.4.3.1 UAE Facial Injectable Market by End-use
6.4.4.3.2 UAE Facial Injectable Market by Product
6.4.4.3.3 UAE Facial Injectable Market by Application
6.4.4.4 Saudi Arabia Facial Injectable Market
6.4.4.4.1 Saudi Arabia Facial Injectable Market by End-use
6.4.4.4.2 Saudi Arabia Facial Injectable Market by Product
6.4.4.4.3 Saudi Arabia Facial Injectable Market by Application
6.4.4.5 South Africa Facial Injectable Market
6.4.4.5.1 South Africa Facial Injectable Market by End-use
6.4.4.5.2 South Africa Facial Injectable Market by Product
6.4.4.5.3 South Africa Facial Injectable Market by Application
6.4.4.6 Nigeria Facial Injectable Market
6.4.4.6.1 Nigeria Facial Injectable Market by End-use
6.4.4.6.2 Nigeria Facial Injectable Market by Product
6.4.4.6.3 Nigeria Facial Injectable Market by Application
6.4.4.7 Rest of LAMEA Facial Injectable Market
6.4.4.7.1 Rest of LAMEA Facial Injectable Market by End-use
6.4.4.7.2 Rest of LAMEA Facial Injectable Market by Product
6.4.4.7.3 Rest of LAMEA Facial Injectable Market by Application

Chapter 7. Company Profiles

7.1 Ipsen Pharma Biotech SAS
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.2 Merz Pharma GmbH & Co. KGaA
7.2.1 Company Overview
7.2.2 Recent Strategies and Developments
7.2.2.1 Partnerships, Collaborations, and Agreements
7.2.2.2 Product Launches and Product Expansions
7.3 Suneva Medical, Inc.
7.3.1 Company Overview
7.4 Medytox Inc.
7.4.1 Company Overview
7.5 Sinclair Pharma Ltd. (Huadong Medicine Co., Ltd.)
7.5.1 Company Overview
7.5.2 Recent Strategies and Developments
7.5.2.1 Product Launches and Product Expansions
7.5.2.2 Approvals and Trials
7.6 Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group)
7.6.1 Company Overview
7.7 Anika Therapeutics, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Prollenium Medical Technologies Inc.
7.8.1 Company Overview
7.8.2 Recent Strategies and Developments
7.8.2.1 Acquisition and Mergers
7.9 Galderma S.A.
7.9.1 Company Overview
7.9.2 Recent Strategies and Developments
7.9.2.1 Partnerships, Collaborations, and Agreements
7.9.2.2 Acquisition and Mergers
7.10. Allergan PLC (AbbVie, Inc.)
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense

Companies Mentioned

Ipsen Pharma Biotech SAS
Merz Pharma GmbH & Co. KGaA
Suneva Medical, Inc.
Medytox Inc.
Sinclair Pharma Ltd.
Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group)
Anika Therapeutics, Inc.
Prollenium Medical Technologies Inc.
Galderma S.A.
Allergan PLC (AbbVie, Inc.)

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3534EUR$3,600USD£2,954GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4240EUR$4,320USD£3,545GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5936EUR$6,048USD£4,963GBP

Facial Injectable Market Size, Share & Industry Trends Analysis Report By End-use (MedSpa, Dermatology Clinics and Hospitals), By Product, By Application, By Regional Outlook and Forecast, 2023 - 2029

Product Outlook

Application Outlook

End-use Outlook

Regional Outlook

Strategies Deployed in the Market